2015-09-14 20:15:19 UTC

AGA Comments on FDA Draft Guidance on Gastroparesis Drugs

Sept. 15, 2015

AGA and FDA are committed to improving drug development for gastroparesis.

The AGA Center for Diagnostics and Therapeutics has submitted comments on FDA's recently released draft guidance document entitled “Gastroparesis: Clinical Evaluation of Drugs for Treatment.” The guidance provides insights on currently available methods to assess the severity of symptoms and efficacy of treatments.

This guidance document is an important step towards refining the process of developing crucial drugs for patients suffering from the effects of gastroparesis. AGA applauds FDA for starting this important discussion.

AGA’s comments center on the following areas:

  • Relationship between biomarkers (such as gastric emptying) and symptoms.
  • Currently available patient-reported outcome instruments.
  • Consideration of alternative trial designs.
  • The value, or lack thereof, of studying patients with idiopathic versus diabetic gastroparesis as separate populations.
  • Defining clinically meaningful changes and endpoints.

Review the FDA draft guidance and AGA's comments.

More on Gastroparesis

2018 Research Grants Open for Applications

Dec. 11, 2017

Don't lose sight of award deadlines during the busy holiday season. Read on to discover open grants from the AGA Research Foundation and when applications are due.

Grant Spotlight: AGA Pilot Awards

Nov. 8, 2017

Take your new research project idea and make it a reality with an AGA research award. Eight grants are open with a Jan. 12, 2018, deadline.

Gastroparesis Treatment: The Future is Bright

Aug. 3, 2017

New drugs are in the pipeline. AGA white paper summarizes drug development for this condition.